Madrigal Pharma Files 8-K on Financial Condition
Ticker: MDGL · Form: 8-K · Filed: Feb 28, 2024 · CIK: 1157601
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-filing
TL;DR
**Madrigal Pharma just filed an 8-K on its financials, so keep an eye out for the details!**
AI Summary
Madrigal Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting on its results of operations and financial condition. The filing, under SEC File Number 001-33277, indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, based in West Conshohocken, Pennsylvania, with a business phone of (267) 824-2827, did not disclose specific dollar amounts or detailed financial results in the provided text, but rather the nature of the filing.
Why It Matters
This filing signals that Madrigal Pharmaceuticals is providing an update on its financial performance, which could impact investor sentiment and future stock performance.
Risk Assessment
Risk Level: low — The filing itself is a standard disclosure and does not inherently indicate a high risk, though the content of the full report could.
Key Players & Entities
- MADRIGAL PHARMACEUTICALS, INC. (company) — Registrant
- February 28, 2024 (date) — Date of earliest event reported
- Delaware (company) — State of incorporation
- 001-33277 (dollar_amount) — Commission File Number
- 04-3508648 (dollar_amount) — IRS Employer Identification No.
- West Conshohocken, Pennsylvania (company) — Principal executive offices location
- 19428 (dollar_amount) — Zip Code
- (267) 824-2827 (dollar_amount) — Registrant's telephone number
FAQ
What is the purpose of this 8-K filing by Madrigal Pharmaceuticals, Inc.?
The 8-K filing by Madrigal Pharmaceuticals, Inc. is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, specifically addressing 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits'.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on February 28, 2024.
What is the Commission File Number for Madrigal Pharmaceuticals, Inc.?
The Commission File Number for Madrigal Pharmaceuticals, Inc. is 001-33277.
Where are Madrigal Pharmaceuticals, Inc.'s principal executive offices located?
Madrigal Pharmaceuticals, Inc.'s principal executive offices are located at Four Tower Bridge, 200 Barr Harbor Drive, Suite 200, West Conshohocken, Pennsylvania, 19428.
What is the business phone number for Madrigal Pharmaceuticals, Inc.?
The business phone number for Madrigal Pharmaceuticals, Inc. is (267) 824-2827.
Filing Stats: 532 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-02-28 07:01:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 Par Value Per Share MDGL The Nasdaq
Filing Documents
- d743882d8k.htm (8-K) — 26KB
- d743882dex991.htm (EX-99.1) — 52KB
- g743882g0227065624928.jpg (GRAPHIC) — 3KB
- 0001193125-24-049116.txt ( ) — 215KB
- mdgl-20240228.xsd (EX-101.SCH) — 3KB
- mdgl-20240228_lab.xml (EX-101.LAB) — 18KB
- mdgl-20240228_pre.xml (EX-101.PRE) — 11KB
- d743882d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MADRIGAL PHARMACEUTICALS, INC. By: /s/ Brian J. Lynch Name: Brian J. Lynch Title: Senior Vice President and General Counsel Date: February 28, 2024